Product Code: SR1323A581_Report
The global vaccine delivery devices market size reached US$ 7.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2028, exhibiting a growth rate (CAGR) of 7.5% during 2023-2028.
A vaccine is a biological substance used to protect individuals from bacterial illnesses by stimulating the immune response of the body against the disease. It helps the immune system to produce antibodies against the invading antigens when given at specific intervals. It can be delivered in the body through liposomes, microspheres, nanoparticles, dendrimers, micellar systems, immune stimulating complexes (ISCOMs), and plant-derived viruses. At present, there is a rise in the utilization of vaccine delivery devices due to the growing prevalence of infectious diseases across the globe.
Vaccine Delivery Devices Market Trends:
- Technological advancements in the systematic delivery of vaccines, such as micro-needles and electroporation, represent one of the key factors driving the market. Moreover, there is an increase in the utilization of needle-free delivery systems as they decrease needle stick injuries and the vaccine antigen dose and enhance the vaccine immunogenicity. This, along with the rising research in the field of vaccines and the development of new vaccine delivery devices around the world, is propelling the growth of the market. In addition, governments of several countries are promoting immunization programs to prevent disabilities and deaths from vaccine-preventable diseases. This, coupled with the growing investments by non-governmental organizations (NGOs) for various vaccination programs and campaigns globally, is positively influencing the market. Besides this, key market players are focusing on novel delivery technologies that increase the therapeutic value of vaccines by reducing toxicity. Additionally, the expanding healthcare sector due to the increasing geriatric population and easy access to medical products and services is bolstering the market growth. Furthermore, the outbreak of coronavirus disease (COVID-19) is augmenting the sales of vaccine delivery devices worldwide.
Key Market Segmentation:
- IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine delivery devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on device, route of administration and end user.
Breakup by Device:
- Syringes
- Jet Injectors
- Others
Breakup by Route of Administration:
- Intramuscular Vaccination
- Intradermal Vaccination
- Subcutaneous Vaccination
- Others
Breakup by End User:
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
- The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Becton Dickinson and Company, Enesi Pharma Limited, Gerresheimer AG, INOVIO Pharmaceuticals, NanoPass, Panacea Biotec Pharma Limited (Panacea Biotec), Pharmajet Inc., Schott AG (Carl-Zeiss-Stiftung), Terumo Corporation and Vaxxas.
Key Questions Answered in This Report:
- How has the global vaccine delivery devices market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global vaccine delivery devices market?
- What are the key regional markets?
- What is the breakup of the market based on the device?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global vaccine delivery devices market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Vaccine Delivery Devices Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Device
- 6.1 Syringes
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Jet Injectors
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Intramuscular Vaccination
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intradermal Vaccination
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Subcutaneous Vaccination
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 3M Company
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Becton Dickinson and Company
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Enesi Pharma Limited
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Gerresheimer AG
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 INOVIO Pharmaceuticals
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 NanoPass
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Panacea Biotec Pharma Limited (Panacea Biotec)
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pharmajet Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Schott AG (Carl-Zeiss-Stiftung)
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 SWOT Analysis
- 14.3.10 Terumo Corporation
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Vaxxas
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio